Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
about
Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gammaReview of the Structural and Dynamic Mechanisms of PPARγ Partial AgonismComputational methods in drug discoveryInsights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligandsIdentification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validationA compound-based proteomic approach discloses 15-ketoatractyligenin methyl ester as a new PPARγ partial agonist with anti-proliferative abilityVirtual Screening as a Technique for PPAR Modulator Discovery.Pharmacophore-driven identification of PPARγ agonists from natural sources.Understanding nuclear receptors using computational methods.Antiviral drugs specific for coronaviruses in preclinical developmentStructural basis for PPARγ transactivation by endocrine-disrupting organotin compounds.Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands.Phosphorylation of PPARγ Affects the Collective Motions of the PPARγ-RXRα-DNA Complex.In silico pharmacology for drug discovery: applications to targets and beyondComputer-aided drug discovery and development (CADDD): in silico-chemico-biological approach.A Role for the PPARgamma in Cancer Therapy.SR2067 Reveals a Unique Kinetic and Structural Signature for PPARγ Partial Agonism.Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.Cross-Talk between PPARgamma and Insulin Signaling and Modulation of Insulin Sensitivity.Probing the intermolecular interactions of PPARγ-LBD with polyunsaturated fatty acids and their anti-inflammatory metabolites to infer most potential binding moieties.PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis.Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes.SAR and Computer-Aided Drug Design Approaches in the Discovery of Peroxisome Proliferator-Activated ReceptorγActivators: A Perspective
P2860
Q24599833-B794454B-11DD-47F8-BF66-2E8B8D977BDBQ26782232-5C1AC9FB-589B-463E-BA5F-2FCF7C516284Q26997089-8B618C6F-624A-43A4-B5B4-479E0077EBD6Q27644330-5BA0C12D-6AD3-479B-8AC6-A0076C3ADEB1Q28485402-61CF8532-8DEE-4FD7-9B57-C032C810730FQ28818450-4669E4EF-4AAC-4CB2-918B-AEB2CD01282CQ33502225-C879BFD4-24E2-455C-9A89-3D6547F7FB79Q33744181-142F49F9-B23D-4C5A-9141-E7E7CC8C38BAQ33755918-9CD74518-F6EA-43BC-9E5E-321294878B53Q34332580-A83035D6-5179-48A8-981E-07A60C29687CQ35089434-916EC007-2EB7-4E4B-8D7D-8C1F4CB52C6CQ35395528-D8E169C2-5657-4C96-9862-01DF492CF664Q35625043-F35A90F9-1D36-4C79-9AF1-9762129FA2A7Q35995265-192A73BF-57A5-4C07-AB45-B7442200E77CQ36477542-719AACF0-C53D-4D67-B018-FE618FC161FBQ36691611-0F15F7ED-5332-4B3E-8CA0-B48A2E129E19Q36760160-1F2466E3-F499-4054-A4F3-193967189077Q37724195-50D8D5D8-BE10-4484-99D4-B8F8E77C35CFQ39209941-AC4E0BF4-8BC9-42D6-A712-AD71C5A7DB50Q42148203-E176813A-BFE7-4559-8865-7F5B19E6C412Q46830543-F8800646-A35B-43AC-AC48-9C8E94205F59Q47111177-5F42AA79-729A-40BB-9AF6-5CCACD9DDC1BQ58919671-62C25EFC-E770-4F00-B679-281D359194CC
P2860
Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Structure-based drug design of ...... in vivo biological activities.
@en
type
label
Structure-based drug design of ...... in vivo biological activities.
@en
prefLabel
Structure-based drug design of ...... in vivo biological activities.
@en
P2093
P356
P1476
Structure-based drug design of ...... /in vivo biological activities
@en
P2093
Andrew Yueh
Chandra M V Goparaju
Chien-Fu Huang
Chiung-Tong Chen
Chun-Chen Liao
Ekambaranellore Prakash
Hsin-Yi Chen
Hwei-Jen Lee
John T-A Hsu
P304
P356
10.1021/JM051129S
P407
P577
2006-05-01T00:00:00Z